Hrt Financial LP Aldeyra Therapeutics, Inc. Transaction History

Hrt Financial LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$1.47 - $6.06 $65,894 - $271,645	44,826 New	44,826 $157,000
Q1 2023 May 12, 2023	BUY	$5.77 - $9.93 $327,747 - $564,043	56,802 Added 71.82%	135,894 $1.35 Million
Q4 2022 Feb 10, 2023	BUY	$5.08 - $7.09 $401,787 - $560,762	79,092 New	79,092 $550,000
Q2 2022 Aug 12, 2022	SELL	$2.43 - $4.85 $270,130 - $539,150	-111,165 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.25 - $5.17 $299,754 - $476,839	92,232 Added 487.15%	111,165 $494,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $66,265 - $182,324	18,933 New	18,933 $75,000
Q2 2021 Aug 16, 2021	SELL	$10.44 - $14.85 $684,227 - $973,254	-65,539 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$6.53 - $14.42 $350,452 - $773,892	-53,668 Reduced 45.02%	65,539 $778,000
Q4 2020 Feb 16, 2021	BUY	$6.31 - $8.13 $752,196 - $969,152	119,207 New	119,207 $817,000
Q3 2020 Nov 13, 2020	SELL	$4.0 - $7.53 $310,972 - $585,404	-77,743 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.97 - $5.05 $153,153 - $392,602	77,743 New	77,743 $324,000

116

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $318M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.